Álamo, Patricia
Pallarès, Victor
Céspedes, María Virtudes
Falgàs, Aïda
Sánchez, Julieta María
Serna, Naroa
Sánchez-García, Laura
Voltà-Durán, Eric
Morris, Gordon A.
Sánchez Chardi, Alejandro
Casanova Rigat, Isolda
Mangues, Ramon
Vázquez Gómez, Esther
Villaverde Corrales, Antonio
Unzueta Elorza, Ugutz
2020
Fluorescent dye labeling is a common strategy to analyze the fate of administered nanoparticles in living organisms. However, to which extent the labeling processes can alter the original nanoparticle biodistribution has been so far neglected. In this work, two widely used fluorescent dye molecules, namely, ATTO488 (ATTO) and Sulfo-Cy5 (S-Cy5), have been covalently attached to a well-characterized CXCR4-targeted self-assembling protein nanoparticle (known as T22-GFP-H6). The biodistribution of labeled T22-GFP-H6-ATTO and T22-GFP-H6-S-Cy5 nanoparticles has been then compared to that of the non-labeled nanoparticle in different CXCR4+ tumor mouse models. We observed that while parental T22-GFP-H6 nanoparticles accumulated mostly and specifically in CXCR4+ tumor cells, labeled T22-GFP-H6-ATTO and T22-GFP-H6-S-Cy5 nanoparticles showed a dramatic change in the biodistribution pattern, accumulating in non-target organs such as liver or kidney while reducing tumor targeting capacity. Therefore, the use of such labeling molecules should be avoided in target and non-target tissue uptake studies during the design and development of targeted nanoscale drug delivery systems, since their effect over the fate of the nanomaterial can lead to considerable miss-interpretations of the actual nanoparticle biodistribution.
Anglès
Protein nanomaterials; Functional materials; Self-assembling nanoparticles; Fluorescent labeling; Biodistribution; Targeting
Instituto de Salud Carlos III PIE15-00028
Instituto de Salud Carlos III PI18-00650
Instituto de Salud Carlos III PI17-00150
Instituto de Salud Carlos III CP19-00028
Instituto de Salud Carlos III CP15-00163
Ministerio de Economía y Competitividad BIO2016-76063-R
Ministerio de Ciencia e Innovación PID2019-105416RB-I00
Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-229
Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-865
Agència de Gestió d'Ajuts Universitaris i de Recerca 2018/FI-B2-00051
Ministerio de Ciencia e Innovación FPU18-04615
Pharmaceutics ; Vol. 12, Issue 11 (November 2020), art. 1004
open access
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
https://creativecommons.org/licenses/by/4.0/